Search

Pharmacological treatment remains essential to control fasciolosis in areas where infection is endemic. However, there are major constraints to treating food-producing animals. Of particular concern is the lack of flukicides for treating early Fasciola infections in ruminant livestock in some countries. In addition, the information provided in package leaflets, particularly regarding withdrawal periods, is often incomplete, confusing, and/or contradictory. International regulatory bodies should harmonize the use of flukicides in livestock in favor of fairer, safer international trade. In addition, monitoring the efficacy of fasciolicides on farms is also essential to minimize the spread of drug-resistant populations of Fasciola. The current situation regarding flukicide formulations in the European Union and other, non-European countries is analyzed in this review paper. Chemotherapy remains the main tool for controlling fasciolosis in endemic areas. However, treatment of ruminant livestock, the main reservoir of the disease, faces severe technical and legal challenges. The scarce number of flukicide drugs is particularly challenging for some productive sectors. Therapeutic failures have been reported for all available flukicides, but the causes have rarely been identified. This situation is a matter of concern and should be considered a research priority. The information provided in package leaflets about the conditions of use of flukicides is not always as detailed and accurate as it should be. Moreover, the efficacy of treatments is not usually monitored. There are unexplained significant differences between countries, and even within some countries, regarding the withdrawal periods established for veterinary medicines with very similar pharmaceutical formulations. [ABSTRACT FROM AUTHOR]